1731 results for "Ketamine"
'Surfing the Silk Road': a study of users' experiences.
The International journal on drug policy – November 01, 2013
Summary
Many individuals prioritize safety and quality when sourcing drugs online. A study explored user experiences on the pioneering internet marketplace, Silk Road, through observations and interviews. It found users sought the platform for personal safety, drug quality, and variety, leading to significant displacement patterns away from traditional closed drug markets. Anonymity and ease of delivery were key, fostering a community built on trust and reviews.
Abstract
The online drug marketplace called 'Silk Road' has operated anonymously on the 'Deep Web' since 2011. It is accessible through computer encrypting ...
LC-MS/MS screening method for designer amphetamines, tryptamines, and piperazines in serum.
Analytical and bioanalytical chemistry – April 01, 2010
Summary
The rapid evolution of designer drugs demands sophisticated detection methods. Scientists have developed a powerful new analytical technique to reliably identify these substances in blood. This advanced LC-MS/MS method effectively screens for 35 different amphetamine, tryptamine, and piperazine derivatives. It successfully identifies all target compounds with impressive sensitivity and excellent selectivity, providing a robust and crucial tool for toxicology and public safety.
Abstract
Since the late 1990s and early 2000s, derivatives of well-known designer drugs as well as new psychoactive compounds have been sold on the illicit ...
Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2).
The international journal of neuropsychopharmacology – August 01, 2010
Summary
Did you know certain addiction treatments and drugs can be actively pumped out of the brain by natural body defenses? Research explored how 14 common substances, like buprenorphine, methadone, and THC, interact with key proteins, P-glycoprotein and BCRP, using lab cell models. Findings show norbuprenorphine, buprenorphine, methadone, ibogaine, and THC inhibited P-glycoprotein. BCRP was also inhibited by buprenorphine, norbuprenorphine, ibogaine, and THC. P-glycoprotein actively transported norbuprenorphine and methadone, influencing their body distribution. This advances understanding of drug movement and interactions.
Abstract
Drug interaction with P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) may influence its tissue disposition including blood-brain ...
Dopamine D2High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil.
Synapse (New York, N.Y.) – August 01, 2009
Summary
Unexpectedly, phencyclidine (PCP), known for other effects, strongly stimulates dopamine D2 receptors in brain tissue. Researchers investigated if PCP and similar substances like LSD and modafinil activate these receptors. Using rat brain samples, they found PCP, hallucinogens, and psychostimulants effectively activate D2 receptors at behaviorally relevant concentrations, a positive discovery that clarifies how these compounds influence brain activity.
Abstract
Although it is commonly stated that phencyclidine is an antagonist at ionotropic glutamate receptors, there has been little measure of its potency ...
Discriminative stimulus effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane in rhesus monkeys.
The Journal of pharmacology and experimental therapeutics – February 01, 2008
Summary
Serotonin receptors are key to how some hallucinogens are perceived. Monkeys learned to distinguish a psychoactive drug from placebo. Blocking serotonin 2A receptors fully prevented the drug's stimulus. Human hallucinogens substituted, confirming 5-HT2A's role. Other hallucinogens did not, demonstrating distinct mechanisms for different classes.
Abstract
Discriminative stimulus effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) and related drugs have been studied extensively in rodents...
The plant-derived hallucinogen, salvinorin A, produces kappa-opioid agonist-like discriminative effects in rhesus monkeys.
Psychopharmacology – March 01, 2004
Summary
A naturally occurring plant hallucinogen, Salvinorin A, surprisingly mimics the brain's response to powerful opioid compounds. Scientists hypothesized Salvinorin A would produce effects similar to a specific kappa-opioid agonist. Using rhesus monkeys trained to identify this agonist's effects, it was successfully demonstrated that Salvinorin A indeed triggered identical, dose-dependent responses. Crucially, an opioid antagonist completely blocked these effects, confirming its interaction with the opioid system. This reveals a fascinating mechanism for this unique hallucinogen.
Abstract
Salvinorin A is the active component of the hallucinogenic plant Salvia divinorum. The potential mode of action of this hallucinogen was unknown un...
Consciousness alterations in a cohort of young Swiss men: Associations with substance use and personality traits.
Frontiers in psychiatry – January 01, 2022
Summary
Over 32% of 2,796 young Swiss men reported experiencing substance-induced altered states of consciousness, with 20.5% experiencing ego dissolution and 16.7% visual pseudo-hallucinations. Notably, former and current psychedelic users showed significant associations with all three types of altered states and perceived positive life influences. In contrast, sociability was negatively linked to these experiences. Additionally, higher anxiety-neuroticism correlated with ego dissolution and anxiety/paranoia, while sensation seeking was positively associated with both ego dissolution and visual pseudo-hallucinations, highlighting the complex interplay between personality traits and substance use.
Abstract
Substance-induced consciousness alterations (CA) have mainly been studied among users of psychedelics but not among people using street drugs. Expl...
Mechanisms of SSRI Therapy and Discontinuation.
Current topics in behavioral neurosciences – January 01, 2024
Summary
SSRIs, commonly prescribed for depression and anxiety, often lead to withdrawal symptoms upon discontinuation, affecting up to 20% of users. While these medications initially boost serotonin levels, their long-term effects involve complex changes in neural plasticity that may improve emotional learning and mood. In contrast, the mechanisms behind SSRI withdrawal remain underexplored, despite evidence showing rebound increases in serotonin neuron excitability after stopping drugs like fluoxetine, citalopram, and paroxetine. This gap highlights the need for a deeper understanding of both therapeutic and withdrawal processes.
Abstract
SSRIs are one of the most widely used drug therapies in primary care and psychiatry, and central to the management of the most common mental health...
Prophylactic effects of arketamine, but not hallucinogenic psychedelic DOI nor non-hallucinogenic psychedelic analog lisuride, in lipopolysaccharide-treated mice and mice exposed to chronic restrain stress.
Pharmacology, biochemistry, and behavior – December 01, 2023
Summary
Arketamine shows remarkable potential as a prophylactic treatment for depression, significantly reducing symptoms in mouse models exposed to chronic stress and inflammation. In a study involving male mice, arketamine administration (10 mg/kg) prior to lipopolysaccharide exposure improved body weight, mobility in forced swimming tests, and prefrontal cortex protein expression. In contrast, neither DOI nor lisuride demonstrated similar long-lasting benefits. These findings highlight arketamine’s unique efficacy against depression-like behaviors linked to chronic stress and inflammatory responses.
Abstract
Anesthetic ketamine and classical psychedelics that act as 5-hydroxytryptamine-2A receptor (5-HT2AR) agonists demonstrated rapid and sustained anti...
Prevalence and Correlates of Past Year Ecstasy/MDMA Use in the United States.
Journal of addiction medicine
Summary
Approximately 0.9% of Americans aged 12 and older reported using ecstasy/MDMA in the past year, based on a survey of 315,661 individuals from 2015 to 2020. Younger age groups showed significantly higher odds of use compared to those aged 35-49, while individuals over 50 were much less likely to use (adjusted odds ratio = 0.14). Bisexual women and racial minorities, including Asians (aOR = 1.92) and Blacks (aOR = 1.70), also exhibited increased odds of use, highlighting specific subpopulations for targeted prevention efforts.
Abstract
3,4-Methylenedioxymethamphetamine (MDMA) (also known as "ecstasy" or "Molly") has regained attention in recent years for its efficacy in treating p...
Addiction specialists' attitudes toward psychedelics: A National Survey.
The American journal on addictions – November 01, 2023
Summary
A significant 70% of 145 addiction specialists surveyed expressed positive attitudes towards the therapeutic use of psychedelics for mental health treatment. However, nearly 30% raised concerns about their potential for addiction. Familiarity with psychedelic research strongly correlated with belief in their therapeutic promise, while fears about addiction negatively impacted perceptions. The findings suggest a growing acceptance of psychedelics among professionals, highlighting an opportunity to enhance education on their risks and benefits. This study uniquely focuses on the perspectives of addiction specialists, filling a notable gap in existing literature.
Abstract
In recent years, there has been accelerating scientific and public interest in the use of psychedelics to treat mental health disorders. Our study'...
Structural identification and metabolic profiling of the new psychoactive substance 2-fluoro-2-oxo-PCPr using NMR and LC-QTOF-MS.
Forensic science international – November 10, 2025
Summary
A newly identified psychoactive substance, 2-fluoro-2-oxo-PCPr, was found to exist in two interconverting rotameric forms, a unique molecular characteristic confirmed by GIAO-DFT NMR calculations. Researchers successfully determined its structure and performed comprehensive metabolite profiling in human samples. Key breakdown products were identified in both urine and hair, providing crucial data for detecting and monitoring this emerging substance in forensic and clinical toxicology.
Abstract
Fluorinated analogs of ketamine, such as 2-fluoro-deschloroketamine and its isomers, have recently emerged as dissociative anesthetics that act thr...
A Systematic Review and Meta-Analysis Investigating the Efficacy of Various Psychedelic Drugs for the Treatment of Substance Use Disorder.
Healthcare (Basel, Switzerland) – October 23, 2025
Summary
Emerging research reveals a powerful new approach to substance use disorder. A comprehensive analysis of human trials shows that psychedelic treatment, utilizing compounds like ibogaine and psilocybin, effectively reduces substance misuse. Ibogaine, in particular, demonstrated the most prominent positive results. These significant benefits were observed whether or not the psychedelic treatment was paired with psychotherapy, highlighting the direct impact of these compounds in addressing substance use disorder.
Abstract
Objectives: This study investigates psychedelic drugs to treat substance use disorder (SUD). Researchers have recently begun conducting clinical tr...
Use and abuse of dissociative and psychedelic drugs in adolescence
Pharmacology Biochemistry and Behavior – January 27, 2021
Summary
Despite widespread adolescent use of Hallucinogens like MDMA and Psilocybin, their specific effects on developing brains are largely unknown. Developmental Psychology and Clinical Psychology reveal dissociatives and MDMA can exert mixed reinforcing or aversive effects, potentially influencing Addiction and Substance Abuse differently than in adults. Psychiatry and Psychedelics and Drug Studies lack crucial data, including direct age-group comparisons or long-term consequences, hindering our understanding of Neurotransmitter Receptor Influence on Behavior. Forensic Toxicology and Drug Analysis urgently require more research on these Drugs of Abuse in adolescents.
Abstract
Adolescence is a period of profound developmental changes, which run the gamut from behavioral and neural to physiological and hormonal. It is also...
Unique Effects of Sedatives, Dissociatives, Psychedelics, Stimulants, and Cannabinoids on Episodic Memory: A Review and Reanalysis of Acute Drug Effects on Recollection, Familiarity, and Metamemory
OpenAlex – May 24, 2022
Summary
Psychedelics surprisingly enhanced familiarity during memory encoding, according to a reanalysis of 10 datasets covering 28 drug conditions. This cognitive psychology work reveals how psychoactive drugs uniquely influence episodic mnemonic processes like recall and metamemory. Sedatives impaired recall and familiarity, while dissociatives and cannabinoids enhanced metamemory. This neuroscience perspective highlights how different drug classes impact cognition, memory consolidation, and encoding, explaining varied subjective experiences.
Abstract
Abstract Despite distinct classes of psychoactive drugs producing putatively unique states of consciousness, there is surprising overlap in terms o...
Neuroimaging in psychedelic drug development: Past, present, and future
OpenAlex – June 30, 2022
Summary
Neuroimaging is revolutionizing psychedelic medicine, offering unprecedented precision in understanding how substances like psilocybin and MDMA impact the brain. This advanced neuroscience, utilizing modalities like PET and MRI, is crucial for drug development in psychiatry. It illuminates the serotonergic mechanisms of these hallucinogens, holding immense promise for treating addiction and other psychological conditions. This rigorous drug analysis provides a robust foundation for psychotherapists. Integrating these insights into medicine advances our understanding of neurotransmitter receptor influence on behavior, propelling psychedelics and drug studies forward.
Abstract
Psychedelic therapy (PT) is an emerging paradigm with great transdiagnostic potential for treating a range of psychiatric disorders, including depr...
“The mushroom was more alive and vibrant”: Patient reports of synthetic versus organic forms of psilocybin
Journal of Psychedelic Studies – October 29, 2024
Summary
For mental health, whole Psilocybe mushrooms and their extracts offer a more natural and superior experience than synthetic psilocybin. Participants in a Psilocybin-Assisted Therapy program for end-of-life distress reported that while synthetic psilocybin, whole *Psilocybe cubensis*, and mycological extract all provided emotional insight and mystical experiences, synthetic psilocybin felt less natural and had an inferior overall quality. This suggests future Psychedelics and Drug Studies in psychology and psychiatry should prioritize natural mushroom compounds in medicine, moving beyond synthetic drug forms.
Abstract
Abstract Interest in psychedelic research in the West is surging, however, clinical trials have almost exclusively studied synthetic compounds such...
Prefrontal Neurophysiological Changes Associated with Subanesthetic Esketamine Accelerating Mice Emergence from Propofol Anesthesia.
Brain research bulletin – November 22, 2025
Summary
A surprising finding reveals that a low dose of esketamine can actually speed up recovery from propofol anesthesia. Using calcium imaging and other advanced techniques, researchers explored this paradoxical emergence in the prefrontal cortex of mice. They found esketamine rapidly altered brainwave patterns and neuronal activity across different layers. Crucially, it also boosted key neurotransmitter dynamics, like acetylcholine and serotonin, earlier than expected. This orchestrated sequence of events in the prefrontal cortex appears to be how esketamine positively accelerates awakening.
Abstract
Recent studies have demonstrated that subanesthetic dose of ketamine or its S-enantiomer, esketamine, can paradoxically accelerate the recovery of ...
Novel Psychoactive Substances—Recent Progress on Neuropharmacological Mechanisms of Action for Selected Drugs
Frontiers in Psychiatry – August 18, 2017
Summary
The evolving view of psychoactive drugs reveals both significant risks and surprising medical potential. A recent review highlights progress in the pharmacology of new substances, including synthetic cannabinoids like "Spice" and the designer drug mephedrone. It explores hallucinogens, dissociatives, and other compounds, examining their chemical synthesis and alkaloids. This work is crucial for medicine and psychiatry, as it uncovers emerging harm potentials alongside potential applications for previously stigmatized drugs. This ongoing evaluation informs our approach to psychedelics and drug studies.
Abstract
A feature of human culture is that we can learn to consume chemical compounds, derived from natural plants or synthetic fabrication, for their psyc...
Psychedelic-Assisted Therapy: Potential Benefits and Challenges in Mental Health Treatment
Medical Science Monitor – June 30, 2025
Summary
Psychedelics offer compelling potential for mental health, addressing severe conditions like depression and PTSD. These substances, including those from chemical synthesis and alkaloids, are explored in Psychiatry and Psychology. A psychotherapist might integrate them into Medicine, yet current Drug Studies, often found in MEDLINE, confirm psychedelic-assisted therapy remains experimental due to a scarcity of large-scale trials. While unique mechanisms, such as those related to Nicotinic Acetylcholine Receptors, are under study, robust evidence is crucial for patients needing intensive care medicine-level attention for complex mental health challenges.
Abstract
Psychedelics, derived from the Greek words "psyche" (soul) and "deloun" (revealing), are substances historically and currently considered "soul-rev...
Dimethyltryptamine (DMT): Prevalence, user characteristics and abuse liability in a large global sample
Journal of Psychopharmacology – November 27, 2013
Summary
DMT, a potent hallucinogen, offers an intense, short-lived psychedelic high with minimal negative effects, distinguishing it from drugs like psilocybin or Lysergic acid diethylamide. A survey of 22,289 individuals revealed 8.9% lifetime use. Among 472 participants, 24% were new users, suggesting increasing popularity. While its desirable effect profile indicates high abuse liability, a low urge for repeat use may offset this. This data from Drug Studies is vital for Psychology, Psychiatry, and Medicine, informing understanding of neurotransmitter receptor influence on behavior and Forensic Toxicology.
Abstract
This paper presents original research on prevalence, user characteristics and effect profile of N,N-dimethyltryptamine (DMT), a potent hallucinogen...
Psychedelic Therapy: A Primer for Primary Care Clinicians—Psilocybin
American Journal of Therapeutics – March 01, 2024
Summary
Psilocybin, a potent hallucinogen and alkaloid, shows remarkable promise as a medicine in psychiatry. Initial clinical trials reported 42%-57% remission for major depressive disorder, potentially surpassing existing antidepressants like Fluoxetine. Larger studies observed 25%-29% remission, still a significant reduction in symptoms. Its pharmacology, influencing neurotransmitter receptors, offers sustained benefits from 1-2 doses. While generally safe, transient adverse effects occur, and one large clinical trial noted 7 cases of suicidal ideation. Psychedelics and drug studies continue to explore its therapeutic potential.
Abstract
Background: The primary psychoactive drug in magic mushrooms, psilocybin, induces profound alterations in consciousness through the 5-HT 2A recepto...
Management of Treatment-Resistant Depression: Challenges and Strategies
Neuropsychiatric Disease and Treatment – January 01, 2020
Summary
Treatment-resistant depression (TRD), a severe Major Depressive Disorder, challenges psychiatry, failing at least 2 antidepressant medicine trials. Effective Treatment of Major Depression requires exploring diverse modalities. Brain stimulation techniques, including Electroconvulsive therapy, Transcranial magnetic stimulation, and Deep brain stimulation, are crucial. Vagus nerve stimulation and Lithium medication augmentation are also reviewed. Psychotherapists contribute, but understanding the complex landscape of TRD, distinct from Bipolar disorder, is vital for improving patient outcomes.
Abstract
Treatment-resistant depression (TRD) is a subset of Major Depressive Disorder which does not respond to traditional and first-line therapeutic opti...
High-resolution tracking of unconfined zebrafish behavior reveals stimulatory and anxiolytic effects of psilocybin
Molecular Psychiatry – January 17, 2024
Summary
A compelling Neuroscience finding reveals the hallucinogen Psilocybin acts as an anxiolytic. In larval zebrafish, a model for Psychedelics and Drug Studies, it facilitated exploration and prevented stress responses. This research, crucial for Psychology, shows psilocybin inhibits serotonin neurons in the dorsal raphe nucleus. Understanding this serotonergic neurotransmitter receptor influence on behavior, like insights from Nicotinic Acetylcholine Receptors Study, is vital for drug development to potentially avoid issues like desensitization.
Abstract
Abstract Serotonergic psychedelics are emerging therapeutics for psychiatric disorders, yet their underlying mechanisms of action in the brain rema...
Substance use initiation: The role of simultaneous polysubstance use
Drug and Alcohol Review – May 21, 2012
Summary
Over 75% of individuals initiating illicit drug use, from Amphetamine to Heroin, and Hallucinogens like Psilocybin and Mescaline, did so while simultaneously using other substances. Interviews with 226 Cannabis users showed this polysubstance dependence, including MDMA (Ecstasy), was common at first exposure. This insight into substance use and abuse is crucial for Psychology, Psychiatry, and Medicine, informing Substance Abuse Treatment and Outcomes. Forensic Toxicology and Drug Analysis could further explore these Psychedelics and Drug Studies.
Abstract
Abstract Introduction and Aims. Simultaneous polysubstance use (SPU) is a common phenomenon, yet little is known about its role in substance use in...
Blinding and expectancy confounds in psychedelic randomized controlled trials
Expert Review of Clinical Pharmacology – May 26, 2021
Summary
Treatment effects for Major Depression from psychedelic clinical trials may be significantly overestimated. A systematic review of Randomized Controlled Trials (RCTs) using MEDLINE revealed many studies on psilocybin and similar psychedelics lacked effective blinding. Expectancy theory suggests participants often discern if they receive the active medicine or a placebo, influencing reported outcomes. This de-blinding means large effect sizes in clinical psychology and psychiatry for these alternative medicine treatments might be inflated. Future drug studies must improve blinding to accurately assess therapeutic potential.
Abstract
Introduction: There is increasing interest in the potential for psychedelic drugs such as psilocybin, LSD and ketamine to treat several mental heal...
Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics
Frontiers in Psychiatry – September 10, 2021
Summary
Psychedelics like psilocybin and LSD show remarkable therapeutic potential for stress-related disorders, offering antidepressant, anxiolytic, and cognitive benefits. Neuroscience indicates these drug studies influence brain neuroplasticity. Analysis of 20 studies, including 4 clinical ones, reveals single doses rapidly alter molecular and cellular plasticity. Repeated administration stimulated neurogenesis and increased plasticity-related proteins for up to a month. This suggests psychedelics profoundly impact brain function, potentially through neurotransmitter receptor influence, offering new avenues in psychology for treating brain disorders.
Abstract
Clinical studies suggest the therapeutic potential of psychedelics, including ayahuasca, DMT, psilocybin, and LSD, in stress-related disorders. The...
A review of psilocybin: chemistry, clinical uses and future research directions
Australian Journal of Chemistry – May 16, 2023
Summary
Public interest in psychedelics like Psilocybin and Lysergic acid diethylamide (LSD) for mental health is soaring, yet robust clinical evidence for their benefits is still developing. These classic hallucinogens, functioning via specific serotonin receptor pharmacology, are being rigorously examined. Psilocybin, a tryptophan-based alkaloid found naturally, is a key focus. Current drug studies are evaluating its chemistry and proposed therapeutic mechanisms for Psychiatry. This review synthesizes the existing evidence base, guiding future chemical synthesis and psychological applications.
Abstract
Classic psychedelics such as psilocybin, ketamine and lysergic acid diethylamide (LSD) are 5HT2A serotonin receptor agonists that produce individua...
Unraveling the Mysteries of Mental Illness With Psilocybin
Cureus – May 27, 2022
Summary
Psilocybin, a potent tryptamine hallucinogen, is emerging as a revolutionary medicine for mental illness. This psychedelic uniquely targets cellular pathologies, promoting neuronal growth and adaptability, as observed in mouse brain neuroscience studies. Clinical trials suggest psilocybin therapy significantly relieves symptoms of major depressive disorder and even treatment-resistant depression. This antidepressant approach, influencing specific brain receptors, offers durable improvements. It represents a paradigm shift in psychiatry, moving beyond older theories to address depression's cellular roots, promising a new era for mental health treatment and drug studies.
Abstract
Current medications have not been effective in reducing the prevalence of mental illness worldwide. The prevalence of illnesses such as treatment-r...
Advances and Pathophysiological Models of Hallucinogenic Drug Actions in Humans: A Preamble to Schizophrenia Research
Pharmacopsychiatry – July 01, 1998
Summary
The pharmacology of hallucinogens like Lysergic acid diethylamide (LSD) and Psilocybin profoundly impacts neurotransmitter systems, offering critical neuroscience insights. Research demonstrates that drug-induced psychosis, and potentially conditions like schizophrenia, involve a complex mechanism of multiple interactive neurotransmitter receptors. Specifically, a dysbalance among three key neurotransmitters—serotonin, glutamate, and dopamine—influences behavior. These psychedelics and dissociative drug studies provide powerful tools for psychology, elucidating neuropsychiatric disorder pathophysiology. Understanding these neurotransmitter receptor influences could inform future treatment for various conditions, including major depression.
Abstract
Recent research into the pharmacological mechanism of hallucinogens (LSD, psilocybin) and dissociative anesthetics (PCP, ketamine) suggest that mul...
Legal highs: staying on top of the flood of novel psychoactive substances
Therapeutic Advances in Psychopharmacology – January 26, 2015
Summary
A startling 81 novel psychoactive substances were identified in 2013 alone, posing a significant challenge for Medicine and Psychiatry. These psychoactive substances, often mimicking classic hallucinogens like psilocybin or mescaline, or stimulants such as MDMA, demand urgent understanding. Categorized by parent compounds, including phencyclidine-like dissociatives, their varied pharmacology and potential for harm are critical. Understanding their Neurotransmitter Receptor Influence on Behavior is vital for Psychology and Psychedelics and Drug Studies, as Forensic Toxicology and Drug Analysis strive to keep pace.
Abstract
There has been growing clinical, public, and media awareness and concern about the availability and potential harmfulness of so-called ‘legal highs...
Brain mechanisms of hallucinogens and entactogens
Dialogues in Clinical Neuroscience – December 31, 2001
Summary
Neuroscience reveals a surprising shared pathway in Psychology: classic hallucinogens like Psilocybin and Mescaline, alongside psychotomimetic anesthetics, disrupt sensory gating. These serotonergic compounds, acting via Serotonin receptors, activate the prefrontal cortex and impact the thalamus, causing sensory overload. This Neurotransmitter Receptor Influence on Behavior contrasts sharply with MDMA. These Psychedelics and Drug Studies show MDMA fosters positive mood by activating prefrontolimbic areas while deactivating the amygdala and thalamus, impacting perception and potentially Memory and Neural Mechanisms.
Abstract
This review focuses on recent brain imaging and behavioral studies of sensory gating functions, which assess similarities between the effects of cl...
User perceptions of the benefits and harms of hallucinogenic drug use: A web-based questionnaire study
Journal of Substance Use – July 30, 2010
Summary
Over 81% of hallucinogen users reported a profound spiritual experience, with over 90% linking classic psychedelics like Psilocybin and Lysergic acid diethylamide to accessing the unconscious mind. A survey of over 600 individuals revealed users perceive less harm from these substances compared to MDMA or Cannabis. Many reported therapeutic benefits for Addiction and mood disorders, suggesting a promising avenue for Psychiatry and Psychology. This highlights the potential for Neurotransmitter Receptor Influence on Behavior, suggesting deeper inquiry in Psychedelics and Drug Studies, extending beyond Cannabis and Cannabinoid Research.
Abstract
This study used a web-based questionnaire to investigate user perceptions of the benefits and harms of hallucinogenic drug use. Over 600 forms were...
Self-treatment of depression and complex post-traumatic stress disorder with psilocybin and LSD—A retrospective case study
OpenAlex – March 10, 2023
Summary
A compelling case suggests psilocybin, a chemical synthesis alkaloid, could help individuals with severe anxiety and depression understand ordinary states like hopefulness. One individual, suffering early trauma and chronic anxiety and depression since childhood, found traditional psychotherapy and psychiatry unhelpful. Through intensive, self-directed psilocybin use from age 19, he reported achieving a foundational feeling of peace by age 30, despite ongoing societal trauma. This clinical psychology insight suggests psychedelics and drug studies may offer new avenues for treating treatment-resistant depression, influencing neurotransmitter receptor behavior.
Abstract
In medicine, psychedelics were initially considered as a tool for clinicians to understand psychotic states. Based on the presented case data, a re...
Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action
Journal of Psychopharmacology – March 19, 2021
Summary
Almost a third of patients with major depressive disorder are non-responders to current antidepressants, a critical challenge in Psychiatry. Promisingly, fast-acting serotonergic hallucinogens like psilocybin, lysergic acid diethylamide, and ayahuasca demonstrate antidepressant and anxiety-reducing effects. Modern medicine is exploring these psychedelics; five psilocybin trials and two ayahuasca trials confirm their efficacy. Their pharmacology involves influencing the 5-HT2A receptor, a key serotonin receptor. These drug studies highlight their profound neurotransmitter receptor influence on behavior, offering new therapeutic avenues beyond traditional serotonin antagonists in Psychology.
Abstract
Major depressive disorder (MDD) is among the most prevalent mental health disorders worldwide, and it is associated with a reduced quality of life ...
Ecstasy and Drug Consumption Patterns: A Canadian Rave Population Study
The Canadian Journal of Psychiatry – August 01, 2002
Summary
Among 210 Montreal rave attendees, a consistent drug experimentation sequence emerged: alcohol, nicotine, cannabis, then Hallucinogens like LSD and Psilocybin. Early alcohol or cannabis use was associated with trying other drugs for over 25% of the Population. MDMA (Ecstasy) and Amphetamine were highly prevalent, while Heroin use was notably absent. This data provides vital insights for Forensic Toxicology and Drug Analysis, informing Psychiatry and Medicine, and contributing to Psychology, Psychedelics and Drug Studies, and Cannabis and Cannabinoid Research.
Abstract
Objective: This study investigates the drug consumption patterns of a sample of rave attendees in the city of Montreal, Quebec, and seeks to identi...
Patterns, Trends, and Meanings of Drug Use by Dance-drug Users in Edinburgh, Scotland
Drugs Education Prevention and Policy – June 01, 2004
Summary
Over 40% of clubbers report anxiety and paranoia, stemming from drug use. A survey of 124 individuals revealed widespread use, with over 80% consuming alcohol, cannabis, and Ecstasy, and 63% using cocaine. These participants, often within dance scenes, cited relaxation and socializing as primary reasons. However, 44% admitted taking too many drugs, and 19% engaged in drug-driving. This psychological data is crucial for clinical psychology, informing medicine and psychiatry regarding substance abuse treatment and outcomes, particularly concerning paranoia and anxiety associated with psychedelics and other drugs.
Abstract
A survey of drug use in the past year was completed by 124 clubbers (50% male, 50% female, age range 14–44, mean 24 years). Participants were self ...
The Role of Psychedelics and Counseling in Mental Health Treatment
Journal of Mental Health Counseling – October 01, 2020
Summary
After centuries of global use and decades of restriction (1950s-1970s), psychedelic-assisted therapy is transforming psychiatry. Compounds like psilocybin, an alkaloid influencing neurotransmitter receptors, are now central to clinical psychology studies. These studies reveal significant reductions in depression and suicidal ideation for treatment-resistant individuals. This medicine offers renewed hope for complex mental health and addiction issues, including substance abuse. Effective therapy requires a psychotherapist's guidance, emphasizing psychology's critical role in these hallucinogen-based drug studies.
Abstract
Psychedelics (i.e., ketamine, methylenedioxymethamphetamine, psilocybin) have been effectively used globally for centuries to treat mental health a...
Exploring Hallucinogen Pharmacology and Psychedelic Medicine with Zebrafish Models
Zebrafish – March 22, 2016
Summary
Hallucinogens like psilocybin and lysergic acid diethylamide are re-emerging as promising treatments for psychiatric disorders. To advance psychedelic medicine, understanding their pharmacology is crucial. Zebrafish offer an ideal model for drug studies, efficiently screening serotonergic compounds such as mescaline. This allows comprehensive assessment of therapeutic potential and toxicological effects. Informing psychology and medicine, this approach facilitates exploring how neurotransmitter receptor influence on behavior can unlock new treatment avenues for brain disorders.
Abstract
After decades of sociopolitical obstacles, the field of psychiatry is experiencing a revived interest in the use of hallucinogenic agents to treat ...
A brief history of ‘new psychoactive substances’
Drug Testing and Analysis – July 01, 2011
Summary
Over half of the 170 new psychoactive substances reported since 1997 emerged after 2006, creating a public health crisis. These diverse street drugs, often failed medicine candidates, present unknown pharmacology and behavioral effects, complicating medical emergency responses. Forensic Toxicology and Drug Analysis faces immense challenges identifying these compounds, including psychedelics, due to absent reference standards. Understanding their Neurotransmitter Receptor Influence on Behavior is vital for psychiatry, but scarce data on these psychoactive substances raises serious concerns about future health impacts.
Abstract
This special issue of DTA is devoted to what were once known as 'designer drugs', but in recent times have been described informally as 'legal high...
The Potential Role of Psychedelic Drugs in Mental Health Care of the Future
Pharmacopsychiatry – May 12, 2021
Summary
Psilocybin and lysergic acid diethylamide (LSD) are revolutionizing mental health treatment, offering new hope in psychiatry. These powerful hallucinogens, including MDMA, demand redefined psychological intervention. Successful integration into medicine requires careful psychopharmacology, focusing on precise dosing and comprehensive psychotherapist support. Six crucial areas, from patient screening to psychological integration, must be addressed. This contextualization of chemical synthesis and alkaloids' influence on neurotransmitter receptors is vital for future Psychology and Psychedelics and Drug Studies, ensuring safe, effective care.
Abstract
Abstract Serotonergic psychedelics such as psilocybin, lysergic acid diethylamide (LSD), or dimethyltryptamine (DMT), as well as psychoactive drugs...
Altered stakes: Identifying gaps in the informed consent process for psychedelic-assisted therapy trials
Journal of Psychedelic Studies – November 20, 2023
Summary
A review of nineteen informed consent forms from psychedelic clinical trials, a biomedical innovation, revealed a critical neuroethics gap. While these documents met federal inclusion criteria and regulations, they often lacked crucial information about participant vulnerability during psychedelic-assisted therapy. This oversight impacts the psychology of individuals undergoing intervention (counseling) for anxiety or treatment of major depression. Robust informed consent protocols are vital for the future of psychiatry and medicine, particularly given the unique nature of psychedelics and drug studies.
Abstract
Abstract Background and aims Psychedelic-assisted therapy (P-AT) has been shown to reduce post-traumatic stress disorder (PTSD), depression, and an...
Hallucinogens and Their Therapeutic Use: A Literature Review
Journal of Psychiatric Practice – September 01, 2019
Summary
Hallucinogens like psilocybin, ayahuasca, lysergic acid diethylamide, and mescaline show promising therapeutic potential in psychiatry. Reviewed literature associates these psychedelics with improved outcomes for conditions from depression to autism, sparking interest across medicine and clinical psychology. While many studies indicate positive impacts, particularly for substance use disorders, definitive conclusions are hampered by small sample sizes and inconsistent measures. Future investigations are crucial to fully understand their neurotransmitter receptor influence on behavior, beyond forensic toxicology and drug analysis.
Abstract
The exploration of possible therapeutic benefits of hallucinogenic substances has undergone a revitalization in the past decade. This literature re...
Is the Requirement for First-Person Experience of Psychedelic Drugs a Justified Component of a Psychedelic Therapist’s Training?
Cambridge Quarterly of Healthcare Ethics – March 02, 2023
Summary
Psychedelics like Psilocybin and MDMA show significant therapeutic potential for conditions from addiction to existential distress, marking a potential step change in Psychiatry. While their value stems from unique experiential learning, questions arise regarding psychotherapist training. Should future psychotherapists undergo hallucinogen experiences themselves? Current thinking suggests requiring such firsthand engagement isn't ethically legitimate without stronger evidence of its unique contribution to understanding psychology. However, permitting voluntary participation in Psychedelics and Drug Studies might be acceptable, acknowledging the diverse academic research themes involved.
Abstract
Abstract Recent research offers good reason to think that various psychedelic drugs—including psilocybin, ayahuasca, ketamine, MDMA, and LSD—may ha...
Trajectories of drug use among French young people: Prototypical stages of involvement in illicit drug use
Journal of Substance Use – January 20, 2016
Summary
Illicit drug use among young people follows distinct patterns. An analysis of 23,882 French 17-year-olds identified two clear groups of illicit drugs (beyond cannabis). The first, including Ecstasy/MDMA and cocaine, typically precedes the second group, featuring drugs like heroin. This distinction in substance use trajectories is crucial for Psychology and Psychiatry, informing targeted prevention within the population, impacting Substance Abuse Treatment and Outcomes, and future prenatal substance exposure effects.
Abstract
Aims: This study investigated patterns and trajectories of substance use, with a special focus on illicit drugs other than cannabis. It examined bo...
Blinding and Expectancy Confounds in Psychedelic Randomised Controlled Trials
OpenAlex – March 08, 2021
Summary
Psychedelics, with their known neurotransmitter receptor influence on behavior, are gaining traction in medicine for treating conditions like major depression. However, a meta-analysis of extant randomized controlled trials in clinical psychology reveals that blinding failures and high patient expectancy, explained by expectancy theory, likely inflate reported large effect sizes from these drug studies. Careful attention to clinical trial design is crucial for accurate assessment.
Abstract
There is increasing interest in the potential for psychedelic drugs such as psilocybin, LSD and ketamine to treat a number of mental health disorde...
Psychedelic Therapy: A Primer for Primary Care Clinicians—Historical Perspective and Overview
American Journal of Therapeutics – March 01, 2024
Summary
MDMA, a synthetic drug, demonstrates superiority over existing treatments for post-traumatic stress disorder in two completed Phase III clinical trials. This highlights the growing potential of psychedelics as medicine in psychiatry. While psilocybin, a naturally occurring hallucinogen, shows a 25-29% depression remission rate in larger trials (100+ participants)—comparable to standard antidepressants at 30%—other compounds like lysergic acid diethylamide and the dissociative Esketamine are also being explored. Understanding their pharmacology and potential adverse effects is crucial as these drug studies advance.
Abstract
Background: Psychedelic drugs have recently emerged as plausibly effective pharmacological agents for the management of depression, anxiety, and ot...
Mapping Pharmacologically-induced Functional Reorganisation onto the Brain’s Neurotransmitter Landscape
OpenAlex – July 13, 2022
Summary
Mind-altering drugs profoundly reorganize brain function by engaging intricate neurotransmitter systems. Neuroscience and Neuropharmacology Research demonstrates that psychoactive substances, including 10 diverse drugs like psychedelics (LSD, psilocybin) and anesthetics, exert their effects based on the brain's molecular makeup. By mapping 19 neurotransmitter receptors and transporters, a clear link emerged between specific neurotransmitter receptor influence on behavior and drug-induced changes. This work in Psychology and Medicine highlights how pharmacology precisely targets brain regions, revealing patterns that even mirror those seen in brain disorders.
Abstract
Abstract To understand how pharmacological interventions can exert their powerful effects on brain function, we need to understand how they engage ...
Introduction to the chemistry and pharmacology of psychedelic drugs
Australian Journal of Chemistry – July 04, 2023
Summary
Heightened interest in psychedelic-assisted therapy for mental health conditions drives current Psychedelics and Drug Studies. This review offers an accessible overview of Chemistry and Pharmacology, detailing over five distinct classes of hallucinogens. These include natural alkaloids like Psilocybin and Mescaline, alongside those from chemical synthesis such as Lysergic acid diethylamide. Understanding their Neurotransmitter Receptor Influence on Behavior is crucial for advancing Psychology and therapeutic applications.
Abstract
The science of psychedelics is an intriguing, multi-disciplinary field that has recently been the subject of heightened public interest. This has m...
Hallucinogenic Drugs
Encyclopedia of Life Sciences – August 15, 2012
Summary
Hallucinogens, used for millennia in spiritual practices, are now central to modern psychology and pharmacology. Potent psychedelics like Lysergic acid diethylamide, Psilocybin, and Mescaline exert their powerful influence on behavior by primarily modulating serotonin neurotransmitter receptors, leading to profound perceptual and cognitive shifts. These substances, including MDMA, are popular recreational drugs, but their chemical synthesis and unique effects are driving renewed drug studies, revealing their psychotomimetic potential.
Abstract
Abstract Hallucinogens constitute one of the oldest classes of drugs used by humanity, often in the context of spiritual practices. Classic halluci...